“Genetic variability is very challenging, and we have to work harder to try and identify what underlies responses [to interventions for cancer-induced pain],” commented David S. Craig, PharmD, Pharmacist Lead–Acute Pain/Supportive Care Medicine, Moffitt Cancer Center. At the NCCN 2022 Annual Conference, Dr. Craig presented pharmacogenetic considerations and related recommendations for the treatment and supportive care of patients with cancer.
Caudle KE, Gammal RS, Whirl-Carrillo M, et al. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm 2016;73:1977–1985.
Rakvåg TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005;116:73–78.
Drewe J, Ball HA, Beglinger C, et al. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol 2000;50:237–246.
Mogil JS, Ritchie J, Smith SB, et al. Melanocortin-1 receptor gene variants affect pain and μ-opioid analgesia in mice and humans. J Med Genet 2005;42:583–587.
Lötsch J, Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. Pain 2006;121:1–5.
U.S. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling. Accessed April 12, 2022. Available at: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
Swarm RA, Youngwerth JM, Agne JL, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Adult Cancer Pain. Version 1.2022. Accessed April 12, 2022. Available at NCCN.org
Lötsch J, Geisslinger G. Are μ-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 2005; 11:82–89.
Sanchez-Covarrubias L, Slosky LM, Thompson BJ, et al. P-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenac. PLoS One 2014;9:e88516.
Moody DE, Liu F, Fang, WB, et al. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism. J Anal Toxicol 2015;39:374–386.
Charpiat B, Tod M, Darnis B, et al. Respiratory depression related to multiple drug–drug interactions precipitated by a fluconazole loading dose in a patient treated with oxycodone. Eur J Clin Pharmacol 2017;73: 787–788.